 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
IMI International Medical Innovations (IMI on Toronto) 21 million shares About 25% owned by insiders www.imin.ca Tuesday November 14, 10:00 am Eastern Time Press Release SOURCE: IMI International Medical Innovations Inc. Non-Invasive Skin Cholesterol Test Identifies People at Risk of Heart Disease Canadian-developed test could be available within six months NEW ORLEANS, Nov. 14 /CNW/ - Canadians may soon have their cholesterol level tested on the palm of their hands, according to research presented today at the American Heart Association meeting in New Orleans. Results of a pivotal clinical trial show that skin cholesterol is an effective way of identifying patients who have a build-up of plaque in their arteries, enabling doctors to treat them earlier before more damage is done. The new test, called Cholesterol 1,2,3(TM), does not involve blood, fasting or waiting hours or days for results. It is a three-minute test done with two drops of liquid on the palm of the hand. A colour change is read with a highly sensitive reader, and provides the health professional with a quantifiable result that indicates the patient's risk for cardiovascular disease. Results of the 400-patient clinical trial show that high levels of skin cholesterol closely parallel coronary artery blockage, which can lead to heart attack. Patients in the trial also underwent angiography (dye injected in the veins through a catheter and viewed) to detect blockages in their arteries. "This is the most important study done on skin cholesterol to date because it compares the test with angiography - the gold standard for diagnosing atherosclerosis," said Dr. Dennis Sprecher, lead investigator for the trial and a cardiologist at The Cleveland Clinic Foundation. "There is a correlation between a patient's skin cholesterol and the number of blood vessels with significant disease, which tells us the skin cholesterol test is an effective predictor of disease." Earlier research done using the skin cholesterol test compared Cholesterol 1,2,3 with stress test results, and showed a strong correlation prompting the latest research. Because angiography is the more commonly accepted standard for measuring coronary artery disease, a trial comparing Cholesterol 1,2,3 to angiography was necessary to demonstrate the test's true effectiveness. Doctor's office, pharmacy and potentially at home Cholesterol 1,2,3 was developed by Canadian predictive medicine company IMI International Medical Innovations Inc. The company expects to submit the product to the Canadian Health Protection Branch for approval early next year, and approval could come as quickly as six weeks later. "Canadians may start seeing Cholesterol 1,2,3 tests in their doctor's office and pharmacy as early as this spring," said Dr. Brent Norton, President of IMI and a family physician. "The research presented at the AHA will form the basis of our submissions to both the Canadian Health Protection Branch and the American FDA." "At the same time, we are continuing research to confirm that skin cholesterol can be used to monitor a patient's response to cholesterol- lowering therapies used by hundreds of thousands of Canadians. That could also lead to a home version of the Cholesterol 1,2,3 test," said Dr. Norton. IMI is a Canadian and world leader in predictive medicine, dedicated to developing innovative products for the rapid and early detection of life- threatening conditions, particularly cardiovascular disease and cancer. IMI is located in Toronto, with shares traded on the Toronto Stock Exchange (TSE: IMI - news). This news release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risk and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings. /NOTE TO PHOTO EDITORS: A photo accompanying this release is available on the Canadian Press Photo Network/ For further information Andrew Weir, Director, Communications, IMI, (416) 222-3449 ext. 27, aweir@imin.ca Sherry Zarins or Ellen Woodger, Veritas Communications Inc., (416) 482-2248, zarins@veritascanada.com | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |